A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1994
11/10/1994	WO1994025453A1 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors
11/10/1994	WO1994025449A1 Oxidation products of cephalomannine
11/10/1994	WO1994025448A1 Novel bisoxadiazolidine derivative
11/10/1994	WO1994025445A1 1,5-benzodiazepines useful as gastrin or cck-antagonists
11/10/1994	WO1994025444A1 3-phenylureido-1,5-benzodiazepine-diones useful as gastrin or cck antagonists
11/10/1994	WO1994025437A1 N-acyl substituted phenyl piperidines as bronchodilators and anti-inflammatory agents
11/10/1994	WO1994025435A1 Peptidyl derivatives and their use as metalloproteinase inhibitors
11/10/1994	WO1994025434A1 Peptidyl derivatives as metalloproteinase inhibitors
11/10/1994	WO1994025431A1 Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl-1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
11/10/1994	WO1994025430A1 Cyclooxygenase and 5-lipoxygenase inhibiting hydroxamic acid derivatives
11/10/1994	WO1994025429A1 4-amino-fluorobenzamides and their use as cytotoxic prodrugs
11/10/1994	WO1994025427A1 Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
11/10/1994	WO1994025073A1 Recombinant viruses and their use in gene therapy
11/10/1994	WO1994025072A1 Rapamycin conjugates and antibodies
11/10/1994	WO1994025070A1 Veterinary composition containing a proton pump inhibitor
11/10/1994	WO1994025066A1 COMBINED TREATMENT OF IRON DEPLETION AND IgG ANTIBODY
11/10/1994	WO1994025059A1 Nutritional transfusion for peripheral vein administration
11/10/1994	WO1994025058A1 Topical compositions for re-epitheliazation of persistent epithelial defects
11/10/1994	WO1994025051A1 Thrombin inhibitors
11/10/1994	WO1994025046A1 Method of combating acyclovir-resistant herpes simplex viral infections
11/10/1994	WO1994025039A1 Composition containing cholestyramine and method of producing the same
11/10/1994	WO1994025038A1 Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis
11/10/1994	WO1994025037A1 Anti-viral guanosine-rich oligonucleotides
11/10/1994	WO1994025034A1 Prevention of myopia by tricyclic compounds
11/10/1994	WO1994025033A1 Use of oral diazoxide for the treatment of disorders in glucose metabolism
11/10/1994	WO1994025032A1 Stabilized injection and method of stabilizing injection
11/10/1994	WO1994025031A1 An exercise hydration regimen to enhance exercise endurance and performance
11/10/1994	WO1994025030A1 SUBSTITUTED DIOXOLO[4,5-g]FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES
11/10/1994	WO1994025029A2 Use of sabeluzole in chronic neurodegenerative diseases
11/10/1994	WO1994025028A1 Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
11/10/1994	WO1994025027A1 Btp receptor modulator of the gabaa/chloride channel complex for prolonging the duration of the gaba induced membrane current
11/10/1994	WO1994025026A1 Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders
11/10/1994	WO1994025025A2 Systems for controlled release of pilocarpine
11/10/1994	WO1994025024A1 Methods of treating hyperlipidemia
11/10/1994	WO1994025023A1 Use of indole derivatives as 5ht1 antagonists
11/10/1994	WO1994025022A1 Rapamycin conjugates and antibodies
11/10/1994	WO1994025020A1 Method and means for inhibiting posterior capsule opacification
11/10/1994	WO1994025019A1 Enhancing performance capacity by sparing muscle glycogen with medium chain fatty acids
11/10/1994	WO1994025018A1 Gaba-ergic modulation of eye growth
11/10/1994	WO1994025017A1 PERNASAL PREPARATION COMPRISING threo-3-(3,4-DIHYDROXYPHENYL)SERINE
11/10/1994	WO1994025016A1 Novel medical use for gaba agonists
11/10/1994	WO1994025015A1 Digestive symptom ameliorant
11/10/1994	WO1994025014A1 Management of cholelithiasis with beta-2-agonists
11/10/1994	WO1994025013A1 Endothelin receptor antagonists
11/10/1994	WO1994025012A2 Medicaments for treatment of migraine, epilepsy and feeding disorders
11/10/1994	WO1994025010A1 Solid form of administration of isosorbide 5-mononitrate
11/10/1994	WO1994025007A1 Stable, ingestable and absorbable nadh and nadph therapeutic compositions
11/10/1994	WO1994025003A1 Nasal aromatic releasing compositions
11/10/1994	WO1994025002A1 Lactulose lozenges
11/10/1994	WO1994024984A2 Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
11/10/1994	WO1994024889A1 Nutrient fats having improved digestibility
11/10/1994	WO1994024886A1 Compositions for administration to animals with coccidiosis
11/10/1994	WO1994024870A1 Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites
11/10/1994	WO1994024867A1 Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
11/10/1994	WO1994024863A1 Aqueous compositions comprising an organic peroxiacid
11/10/1994	WO1994023048A3 Gibbon ape leukemia virus-based retroviral vectors
11/10/1994	WO1994012649A3 Gene therapy for cystic fibrosis
11/10/1994	DE4339934A1 Ovulation-inhibiting composition for hormonal contraception
11/10/1994	DE4314966A1 2-Hydroxyphenyl-substituted isoxazoles, the use thereof as pharmaceutical agents and pharmaceutical compositions containing them
11/10/1994	CA2662090A1 New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
11/10/1994	CA2162157A1 Polyoxime compounds and their preparation
11/10/1994	CA2162056A1 Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites
11/10/1994	CA2161980A1 Substituted methylenedioxy¬3',4':6,7\|indolizino-¬1,2-b\|quinolinones
11/10/1994	CA2161784A1 Enhancing performance capacity by sparing muscle glycogen with medium chain fatty acids
11/10/1994	CA2161695A1 N-acyl substituted phenyl piperidines as bronchodilators and anti-inflammatory agents
11/10/1994	CA2161681A1 Water soluble derivatives of camptothecin and their use as antitumor agents
11/10/1994	CA2161679A1 Recombinant virus and their use in genic therapy
11/10/1994	CA2161656A1 Combined treatment of iron depletion and igg antibody
11/10/1994	CA2161548A1 Phosphoramidates useful as antitumor agents
11/10/1994	CA2161544A1 Cyclooxygenase and 5-lipoxygenase inhibiting n(3-biphenylyl- 1(s)-methyl-2-propenyl) acetohydroxamic acid derivatives
11/10/1994	CA2161531A1 Dna profiles as an indicator of cellular redox potential and cancer risk
11/10/1994	CA2161520A1 Systems for controlled release of pilocarpine
11/10/1994	CA2161427A1 Pyrido(1,2,3-de)quinoxaline derivatives, process for preparing the same and their use in medicaments
11/10/1994	CA2161426A1 Benzo[f]quinoxalindione derivatives, their preparation and their use in drugs
11/10/1994	CA2161425A1 Quinoxalindione derivatives, their preparation and their use in drugs
11/10/1994	CA2161332A1 Use of oral diazoxide for the treatment of disorders in glucose metabolism
11/10/1994	CA2161243A1 Antiviral guanosine-rich oligonucleotides
11/10/1994	CA2161239A1 Spirostanyl glycosidal crystalline monohydrate
11/10/1994	CA2161230A1 Novel peptide nucleic acids
11/10/1994	CA2161130A1 Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
11/10/1994	CA2161116A1 Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders
11/10/1994	CA2161114A1 Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
11/10/1994	CA2161101A1 Rapamycin conjugates and antibodies
11/10/1994	CA2160989A1 Novel bisoxadiazolidine derivative
11/10/1994	CA2160914A1 Endothelin receptor antagonists
11/10/1994	CA2160795A1 Heterocyclic derivatives
11/10/1994	CA2160365A1 Use of sabeluzole in chronic neurodegenerative diseases
11/10/1994	CA2160247A1 Composition containing cholestyramine and method of producing the same
11/10/1994	CA2159990A1 2-,3-,4-,5-,6-,7-,8-,9-and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
11/10/1994	CA2159834A1 Thrombin inhibitors
11/10/1994	CA2159508A1 Method of enhancing thrombolysis
11/10/1994	CA2139569A1 Aqueous compositions comprizing and organic peroxyacid
11/10/1994	CA2139224A1 Agent acting on the central nervous system, method for its preparation and pharmaceutical compositions containing such agent
11/10/1994	CA2139129A1 Peptidyl derivatives and their use as metalloproteinase inhibitors
11/10/1994	CA2139128A1 Peptidyl derivatives as metalloproteinase inhibitors
11/10/1994	CA2138643A1 Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis
11/09/1994	EP0652754A4 Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application.
11/09/1994	EP0633773A4 Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid.
11/09/1994	EP0623629A1 Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing the same
11/09/1994	EP0623627A1 Sulfonamide derivatives

1 ... 7067 7068 7069 7070 7071 7072 7073 7074 7075 7076 7077 7078 7079 7080 7081 7082 7083 7084 7085 7086 7087 ... 7860